Proof of concept and development of a PSMA-targeting NO-releasing PDE5 inhibitor to explore eradication for metastatic prostate cancer

Research unit

INNOSUISSE

Project number

132.906 IP-LS

Project title

Proof of concept and development of a PSMA-targeting NO-releasing PDE5 inhibitor to explore eradication for metastatic prostate cancer

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Topadur continues the lead optimization program to identify an innovative and unique PSMA-targeting NO-releasing PDE5 inhibitor to boost radioligand therapy in advanced prostate cancer and to generate pivotal data to support partnering development with a big pharma.